Suppr超能文献

肌肉减少症各组成部分在预测不良结局方面的累积和增量价值。

Cumulative and Incremental Value of Sarcopenia Components on Predicting Adverse Outcomes.

作者信息

Lam Freddy M H, Su Yi, Lu Zhi-Hui, Yu Ruby, Leung Jason C S, Kwok Timothy C Y

机构信息

Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong; Jockey Club Centre for Osteoporosis Care and Control, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong.

Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong.

出版信息

J Am Med Dir Assoc. 2020 Oct;21(10):1481-1489.e3. doi: 10.1016/j.jamda.2020.05.056. Epub 2020 Aug 5.

Abstract

OBJECTIVES

To examine the incremental value of sarcopenia components, following the diagnosis algorithm of the Asian consensus, on predicting adverse outcomes.

DESIGN

A prospective cohort study.

SETTING AND PARTICIPANTS

Four thousand community-dwelling Chinese adults (2000 men) aged 65 years or older in Hong Kong (mean age = 72.5 ± 5.2).

METHODS

SARC-F was used as the initial predictor of 9 adverse outcomes. In step 2, muscle strength (ie, grip strength) and/or functions (ie, chair-stand, walking speed) were added on top of SARC-F. In step 3, height-, weight-, and body mass index-adjusted appendicular skeletal mass (ASM) measured by dual-energy x-ray absorptiometry (DXA) were added separately to all models formulated in step 2. The areas under the receiver operating characteristic curve (AUCs) were calculated for the models formulated in all steps. Each cumulative AUC would be compared with the AUC yielded in the previous step to evaluate the incremental prediction value.

RESULTS

On top of SARC-F, assessing grip strength, walking speed, or 5-time chair-stand significantly increased the AUC for most adverse outcomes. In particular, assessing both grip strength and gait speed yielded the highest AUC in most prediction models (AUC = 0.539-0.770) and significantly increased the AUC for all outcomes except for recurrent falls. With both muscle strength and function assessed, adding ASM failed to significantly increase the AUC except for 2 conditions. In the 2 conditions, however, a higher height-adjusted ASM was associated with a higher risk of having worsened physical limitations [OR 1.25, 95% confidence interval (CI) 1.12-1.40] and decline in the physical quality of life (OR 1.18, 95% CI 1.06-1.33) in women.

CONCLUSIONS AND IMPLICATIONS

Assessing muscle strength and function provides additional power to predict adverse outcomes on top of SARC-F. Further assessment of muscle mass with DXA provides no extra constructive value ito bettering the prediction regardless of the adjustment parameters. Alternative technologies to measure muscle mass might be required.

摘要

目的

根据亚洲共识诊断算法,研究肌肉减少症各组成部分在预测不良结局方面的增量价值。

设计

一项前瞻性队列研究。

地点和参与者

香港4000名65岁及以上的社区居住中国成年人(2000名男性)(平均年龄 = 72.5 ± 5.2岁)。

方法

SARC - F被用作9种不良结局的初始预测指标。在第二步中,在SARC - F的基础上增加肌肉力量(即握力)和/或功能(即从座椅站起、步行速度)。在第三步中,将通过双能X线吸收法(DXA)测量的身高、体重和体重指数调整后的四肢骨骼肌质量(ASM)分别添加到第二步中构建的所有模型中。计算所有步骤中构建的模型的受试者工作特征曲线下面积(AUC)。将每个累积AUC与上一步产生的AUC进行比较,以评估增量预测价值。

结果

在SARC - F的基础上,评估握力、步行速度或5次从座椅站起显著增加了大多数不良结局的AUC。特别是,在大多数预测模型中,同时评估握力和步态速度产生了最高的AUC(AUC = 0.539 - 0.770),并且除了反复跌倒外,显著增加了所有结局的AUC。在同时评估肌肉力量和功能的情况下,除了2种情况外,添加ASM未能显著增加AUC。然而,在这2种情况中,较高的身高调整后的ASM与女性身体功能受限恶化风险较高[比值比(OR)1.25,95%置信区间(CI)1.12 - 1.40]以及生活质量下降(OR 1.18,95% CI 1.06 - 1.33)相关。

结论与启示

评估肌肉力量和功能在SARC - F的基础上为预测不良结局提供了额外的能力。无论调整参数如何,用DXA进一步评估肌肉质量对改善预测没有额外的建设性价值。可能需要替代技术来测量肌肉质量。

相似文献

2
Defining sarcopenia in terms of incident adverse outcomes.从偶发性不良结局的角度定义肌肉减少症。
J Am Med Dir Assoc. 2015 Mar;16(3):247-52. doi: 10.1016/j.jamda.2014.11.013. Epub 2014 Dec 23.
3
A 3-Item SARC-F.一个三项目 SARC-F。
J Am Med Dir Assoc. 2018 Mar;19(3):223-228. doi: 10.1016/j.jamda.2017.09.006. Epub 2017 Nov 1.
4
Validating the SARC-F: a suitable community screening tool for sarcopenia?验证SARC-F:一种适用于肌少症的社区筛查工具?
J Am Med Dir Assoc. 2014 Sep;15(9):630-4. doi: 10.1016/j.jamda.2014.04.021. Epub 2014 Jun 16.
6
Sarcopenic Obesity Revisited: Insights From the Mr and Ms Os Cohort.肌少症性肥胖再探讨:来自 Mr 和 Ms Os 队列的新见解。
J Am Med Dir Assoc. 2018 Aug;19(8):679-684.e2. doi: 10.1016/j.jamda.2018.03.003. Epub 2018 Apr 17.

引用本文的文献

9
Elevating the findings by substituting in "ISarcoPRM".通过代入“ISarcoPRM”来提升研究结果。
J Neurooncol. 2024 May;168(1):185-186. doi: 10.1007/s11060-024-04653-y. Epub 2024 Apr 2.
10
Computed tomography cannot see "Sarcopenic Obesity".计算机断层扫描无法检测出“肌少症性肥胖”。
Int Urol Nephrol. 2024 Aug;56(8):2809-2810. doi: 10.1007/s11255-024-04030-8. Epub 2024 Mar 17.

本文引用的文献

2
Sarcopenia: A Time for Action. An SCWD Position Paper.肌肉减少症:行动的时刻。SCWD 立场文件。
J Cachexia Sarcopenia Muscle. 2019 Oct;10(5):956-961. doi: 10.1002/jcsm.12483. Epub 2019 Sep 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验